Several pharmaceutical companies, including j&j, are increasing their manufacturing presence in the us. This move appears to be part of a broader trend in the industry, with companies such as lilly, abbvie, novartis, roche, sanofi, and gilead also investing in us production. The expansion of us manufacturing may be related to tariffs imposed on certain products, although the impact of these tariffs is uncertain due to possible exemptions.